Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE:ZH, SEHK:2390), Roborock (SHSE:688169), UBTech (SEHK:9880), WeRide (NASDAQ:WRD), HyperStrong (SHSE:688411), Insta360 (SHSE:688775), Unisound (SEHK:9678), Gan & Lee Pharmaceuticals (SHSE:603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE:688520), Yuanxin Technology, Insilico Medicine, Medilink Therapeutics, LaNova Medicines, zai, StepFun, among many others.

설립

2006

직원

200+

산업

벤처 캐피탈 및 사모펀드 원칙

회사 유형

Partnership

본사

🇭🇰Hong Kong